Mizuho analyst Graig Suvannavejh lowered the firm’s price target on Cerevel Therapeutics to $28 from $32 and keeps a Neutral rating on the shares post the Q3 results. The analyst attributes the decline in shares to concerns around announced 2023 data delays for tavapadon and CVL-871.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CERE:
- Cerevel Therapeutics initiated with a Buy at Loop Capital
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Cerevel Therapeutics initiated with a Buy at BofA
- Cerevel Therapeutics to Report Third Quarter 2022 Financial Results and Pipeline Update on Tuesday, November 8, 2022
- Cantor starts ‘uniquely differentiated’ Cerevel with Overweight, $41 target
